Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.52 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868786 | 0.86 | FFAR4 (0.54) | FFAR4MRGPRX4FFAR1 | |
| SCHEMBL9946087 | 0.86 | FFAR4 (0.52) | FFAR4MRGPRX4FFAR1 | |
| SCHEMBL6957559 | 0.86 | MRGPRX4 (0.54) | FFAR4MRGPRX4MAOBIDO1 | |
| SCHEMBL9946086 | 0.82 | MAOB (0.49) | FFAR4MRGPRX4MAOBIDO1FFAR1 | |
| SCHEMBL26581173 | 0.81 | IDO1 (0.45) | FFAR4MRGPRX4MAOBIDO1FFAR1 | |
| SCHEMBL3763759 | 0.79 | MRGPRX4 (0.70) | FFAR4MRGPRX4MAOBIDO1FFAR1 | |
| SCHEMBL15219285 | 0.79 | MAOB (0.49) | FFAR4MRGPRX4MAOBIDO1MAOA | |
| SCHEMBL8283224 | 0.78 | FFAR4 (0.56) | FFAR4MRGPRX4MAOBIDO1MAOA | |
| SCHEMBL15701557 | 0.78 | MRGPRX4 (0.67) | FFAR4MRGPRX4MAOBIDO1MAOA | |
| SCHEMBL9946057 | 0.76 | MAOB (0.60) | MRGPRX4MAOBIDO1FFAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | FFAR4 1371/4885MRGPRX4 243/4885MAOB 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.